Northborough, MA, United States of America

Kevin Guckian

This inventor holds 40 USPTO granted patents and 15 published patent applications, plus 4 CIPO patents and 19 EPO patents, primarily in O-Glycoprotein Inhibitors. Top assignees: Biogen Ma Inc., Biogen Idec Ma Inc., Sunesis Pharmaceuticals, Inc.. Active years: 2012-2026.

USPTO Granted Patents = 40 (Patent Applications = 15)

% Patents Active = 85.0

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 19 (Patent Applications = 32)

Average Co-Inventor Count = 8.7

ph-index = 8

Forward Citations = 162(Granted Patents)

Location History:

Marlborough, MA (US) (2012 - 2018)
Northborough, MA (US) (2014 - 2021)
Cambridge, MA (US) (2017 - 2022)

Company Filing History:

Sunesis Pharmaceuticals, Inc.

patents

4. 2 out of 854

Millennium Pharmaceuticals Limited

Millenium Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

O-Glycoprotein Inhibitors

S1P Modulating Agents

IRAK4 Inhibitors

Pyridinonyl PDK1 Inhibitors

Heterobicyclic Compounds

Aryl Sphingosine Analogues

Bicyclic Ether Compounds

Azetidinyl Inhibitors

Morpholinyl Compounds

Bicyclic Aryl Compounds

ATX Modulating Agents

Heterocyclic Compounds

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12565504 - Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors (2026-03-03),

2. 12522595 - Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors (2026-01-13),

3. 12421224 - Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors (2025-09-23),

4. 12319679 - Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors (2025-06-03),

5. 12275728 - O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors (2025-04-14),

6. 12180205 - O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors (2024-12-31),

7. 11459324 - O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors (2022-10-04),

8. 11427561 - IRAK4 inhibiting agents (2022-08-30),

9. 10894040 - S1P modulating agents (2021-01-19),

10. 10577367 - IRAK4 inhibiting agents (2020-03-03),

11. 10406144 - SIP modulating agents (2019-09-10),

12. 10273234 - Compounds that are S1P modulating agents and/or ATX modulating agents (2019-04-30),

13. 10246456 - IRAK4 inhibiting agents (2019-04-02),

14. 10166250 - Bicyclic aryl sphingosine 1-phosphate analogs (2019-01-01),

15. 10081646 - Heterobicyclic sphingosine 1-phosphate analogs (2018-09-25),

Title: The Innovative Mind of Kevin Guckian

Introduction: Kevin Guckian, a talented inventor hailing from Northborough, MA (US), is known for his groundbreaking contributions to the world of technology and innovation.

Latest Patents: Kevin Guckian has recently been granted several patents for his cutting-edge inventions in the fields of robotics and artificial intelligence, showcasing his continuous commitment to pushing the boundaries of technological advancement.

Career Highlights: With a career spanning over two decades, Kevin Guckian has established himself as a visionary in the tech industry. His work has revolutionized the way we interact with machines, with a particular focus on enhancing efficiency and user experience.

Collaborations: Throughout his career, Kevin Guckian has collaborated with leading tech companies and research institutions to further develop his inventions. His ability to work in multidisciplinary teams has led to the creation of innovative solutions that have had a lasting impact on the industry.

Conclusion: Kevin Guckian's passion for innovation and his relentless drive to create have solidified his position as a prominent figure in the world of technology. His inventive spirit continues to inspire future generations of inventors to think outside the box and pursue their creative visions.